| Novartis Pharma Schweiz AG - Tasigna 150 mg, Kapseln | | 58007 | | 02 | | Tasigna 150 mg | | Kapseln | | L01EA03 | | Nilotinib | | 24.08.2010 | | |
| | Composition | | nilotinibum 150 mg ut nilotinibi hydrochloridum monohydricum, lactosum monohydricum 117.08 mg, crospovidonum, poloxamerum 188, silica colloidalis anhydrica, magnesii stearas, Kapselhülle: gelatina, E 171, E 172 (rubrum), E 172 (flavum), Drucktinte: lacca, E 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Active Agent | Dose |
|---|
| Nilotinibum | 150 mg |
| | BAG: Active Agent | Dose |
|---|
| Nilotinibum | 150 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| (Flavum) | | | | (Nigrum) | | | | (Rubrum) | | | | Ammoniae Solutio | 28 | | | Crospovidonum | | | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Lacca | | Drucktinte | | Lactose Monohydrate | 117.08 mg | | | Magnesii Stearas | | | | Per Centum | | | | Poloxamer | 188 | | | Pro Capsula | | | | Propylenglycol | | | | Silica Colloidalis Anhydrica | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 004 | 112 Capsule(s) | 1876.76 | 1999.75 | A | SL | No |
|
|
